Company

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout
ELI Radiopharma

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

Hangzhou Eli Radiopharma Co., Ltd. ("Eli Radiopharma") announced the completion of a Series A financing round raising nearly RMB 400 million, capital that will be primarily deployed to advance the…

Amgen's Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren's Disease Activity

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
MabPharm's CMAB807 Biosimilar Infliximab Approved in Pakistan
Auto-immuneBiosimilars

MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan

Zhaoke Ophthalmology's NVK002 ANDA Accepted for Review by China's NMPA
HKG: 0950HKG: 6622

Zhaoke Ophthalmology’s NVK002 ANDA Accepted for Review by China’s NMPA

Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment
CancerClinical trial approval / initiation

Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment

SCG Cell Therapy's SCG142 Receives NMPA Approval for HPV-Related Solid Tumor Clinical Trial
CAR-TCell-therapy

SCG Cell Therapy’s SCG142 Receives NMPA Approval for HPV-Related Solid Tumor Clinical Trial

Show More